Home
Alembic Pharmaceuticals Ltd EPS

Alembic Pharmaceuticals Ltd
NSE: APLLTD
EPS
Key Highlights
- The Earning per Share of Alembic Pharmaceuticals Ltd is ₹ 30.26 as of 02 Apr 25 .
- The earning per share of Alembic Pharmaceuticals Ltd changed from ₹ 6.14 to ₹ 7.01 over 7 quarters. This represents a CAGR of 7.87% .
Historical Earning per Share of Alembic Pharmaceuticals Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Alembic Pharmaceuticals Ltd
Company Fundamentals for Alembic Pharmaceuticals Ltd
Market Cap
17,399 Cr
EPS
30.3
P/E Ratio (TTM)
29.3
P/B Ratio (TTM)
3.6
Day’s High
924.6
Day’s Low
885.0
DTE
0.2
ROE
13.2
52 Week High
1296.15
52 Week Low
725.6
ROCE
12.8
Market Price of Alembic Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
02 Apr 2025 | 885.2 |
01 Apr 2025 | 897.55 |
28 Mar 2025 | 929.25 |
27 Mar 2025 | 930.9 |
26 Mar 2025 | 904.75 |
25 Mar 2025 | 935.25 |
24 Mar 2025 | 963.3 |
21 Mar 2025 | 947.75 |
20 Mar 2025 | 834.15 |
19 Mar 2025 | 841.7 |
SWOT Analysis Of Alembic Pharmaceuticals Ltd
BlinkX Score for Alembic Pharmaceuticals Ltd
Asset Value vs Market Value of Alembic Pharmaceuticals Ltd
Market Value
₹ 17,400
Asset Value
Value addition
4.1 X
₹ 3,379
* All values are in ₹ crores
Competitive Comparison of EPS
Company | Market Cap | EPS |
---|
Alembic Pharmaceuticals Ltd | 17399 | 30.26 |
Sun Pharmaceutical Industries Ltd | 411306 | 49.16 |
Divis Laboratories Ltd | 150343 | 77.86 |
Cipla Ltd | 117323 | 61.78 |
Torrent Pharmaceuticals Ltd | 108614 | 55.02 |
Mankind Pharma Ltd | 99891 | 49.48 |
Company | |
---|---|
Alembic Pharmaceuticals Ltd | 17399 |
Sun Pharmaceutical Industries Ltd | 411306 |
Divis Laboratories Ltd | 150343 |
Cipla Ltd | 117323 |
Torrent Pharmaceuticals Ltd | 108614 |
Mankind Pharma Ltd | 99891 |
Historical Market Cap of Alembic Pharmaceuticals Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Alembic Pharmaceuticals Ltd
Historical Revenue of Alembic Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Alembic Pharmaceuticals Ltd
Historical EBITDA of Alembic Pharmaceuticals Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Alembic Pharmaceuticals Ltd
Historical Net Profit of Alembic Pharmaceuticals Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Alembic Pharmaceuticals Ltd
Dividend Payout Over Time
Alembic Pharmaceuticals Ltd News Hub
Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) f
Read more
13 Aug 24
Alembic Pharma gets US FDA nod for anticoagulant Dabigatran
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa
Read more
13 Aug 24
Alembic Pharmaceuticals Ltd leads losers in 'A' group
Steel Authority of India Ltd, IFCI Ltd, Coffee Day Enterprises Ltd and Orient Cement Ltd are among t
Read more
09 Aug 24
Alembic Pharma Q1 PAT rises 12% YoY to Rs 135 cr
Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 J
Read more
08 Aug 24
Document
Concalls
Feb 2023
TranscriptNov 2022
TranscriptAug 2022
TranscriptMay 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptMay 2021
TranscriptFeb 2023
TranscriptNov 2022
TranscriptAug 2022
TranscriptMay 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptMay 2021
Transcript